Journal of Medical Economics

Below are listed all papers published in the Journal of Medical Economics since January 1998; click on the reference to access the full abstract. Copies of all papers are available direct from the publisher � please contact us for further information.

• Economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events
  J Med Econ: 50



• Longitudinal glaucoma treatment patterns with brinzolamide versus dorzolamide
  J Med Econ: 49



• Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom
  J Med Econ: 48



• Economic evaluation of rabeprazole, omeprazole and ranitidine in the treatment of acid-related upper gastrointestinal disorders
  J Med Econ: 47



• The cost effectiveness of eformoterol via Turbohaler® and salmeterol via pressurised metered dose inhaler and metered dose powder inhaler in mild to moderate asthma
  J Med Econ: 45



• Flora pro.activ: a clinical and financial impact analysis
  J Med Econ: 44



• The clinical and financial impact of oral triptans in the management of migraine in the UK: a systematic review
  J Med Econ: 43



• Secondary prevention with statin therapy: a budgetary-impact assessment for UK primary care
  J Med Econ: 40



• Economic evaluation of inhalers used in the treatment of asthma.
  J Med Econ 1998; 1: 1-18



• Nabumetone compared with Ibuprofen and a weighted NSAID combination: an economic evaluation.
  J Med Econ 1998; 1: 19-39



• Costing anaesthetic practice: reconciling perspectives and approaches.
  J Med Econ 1998; 1: 41-49



• The management of acid-related disorders: the burden of disease and the need for effective treatment.
  J Med Econ 1998; 1: 51-67



• Risperidone: An assessment of its economic benefits in the treatment of schizophrenia.
  J Med Econ 1998; 1: 103-134



• Resource use in general anaesthesia: a comparison of practice in Germany, France and the UK.
  J Med Econ 1998; 1: 135-147



• Economic evaluation of the use of Innohep in the treatment of acute pulmonary embolism.
  J Med Econ 1998; 1: 148-162



• Improving quality in economic evaluations of the management of schizophrenia.
  J Med Econ 1998; 1: 163-176



• Pharmacoeconomic considerations of selective serotonin reuptake inhibitors (SSRIs) within the European Union.
  J Med Econ 1998; 1: 177-187



• L-carnitine in the management of patients after acute myocardial infarction: a cost effectiveness analysis in Italy.
  J Med Econ 1998; 1: 189-200



• Model to evaluate the cost-effectiveness of different antibiotics in the management of acute bacterial exacerbations of chronic bronchitis in Germany.
  J Med Econ 1998; 1: 201-218



• SSRI antidepressant selection and concomitant prescribing of anxiolytics and sedative-hypnotics: evidence from primary care in the United Kingdom.
  J Med Econ 1998; 1: 219-233



• Economic burden of amyotrophic lateral sclerosis in the United Kingdom.
  J Med Econ 1998; 1: 235-245



• Model to evaluate the cost-effectiveness of different antibiotics in the management of community-acquired pneumonia in Germany.
  J Med Econ 1998; 1: 247-261



• Economic implications of the Total Ischaemic Burden Bisoprolol Study (TIBBS) follow-up.
  J Med Econ 1998; 1: 263-280



• Modelling the long-term cost-effectiveness of riluzole for the treatment of amyotrophic lateral sclerosis
  J Med Econ 1999; 2: 1-14



• Cost of managing constipation among terminally ill cancer patients treated with transdermal fentanyl and 12 hour sustained-release morphine in Canada
  J Med Econ 1999; 2: 15-32



• Cost-effectiveness implications of increased survival with anastrozole in the treatment of advanced breast cancer
  J Med Econ 1999; 2: 33-43



• Cost of NSAID adverse effects to the UK National Health Service
  J Med Econ 1999; 2: 45-55



• The economic advantages of response in the treatment of advanced breast cancer
  J Med Econ 1999; 2: 57-63



• Cost-effectiveness of Viridal Duo compared to MUSE and Viagra in the treatment of erectile dysfunction in the UK � a preliminary model
  J Med Econ 1999; 2: 65-83



• Modelling the cost-effectiveness of nevirapine triple combination therapy and dual combination therapy for the treatment of HIV disease in the United Kingdom
  J Med Econ 1999; 2: 85-105



• Therapy Cost 2000: a computer model for pharmacoeconomic analysis
  J Med Econ 1999; 2: 107-115



• Bambuterol is a more cost-effective treatment strategy than salmeterol in asthmatic patients with nocturnal symptoms
  J Med Econ 1999; 2: 117-122



• An economic comparison of the net clinical benefit and treatment costs of raltitrexed and 5-fluorouracil + leucovorin (Mayo regimen) in advanced colorectal cancer.
  J Med Econ 1999; 2: 123-132



• The Cost of Obesity in the United Kingdom.
  J Med Econ 1999; 2: 143-153



• Cost-effectiveness of desirudin in the prevention of the thromboembolic complications of surgery.
  J Med Econ 1999; 2: 155-166



• Mucodyne: the economics of preventing surgery for grommets
  J Med Econ 1999; 2: 167-176



• Economic impact of Elantan LA compared to Isordil, Tenormin and Tildiem LA in the treatment of stable angina in the UK
  J Med Econ 2000; 3: 1-20